Feature | May 22, 2014

Nearly All ICD Implants Performed on Insured Patients

Majority of ICD patients are also male — new study presented at HRS from more than 160,000 ICD implants

ICD Implants Heart Rhythm Society Clinical Study Insurance Male

May 22, 2014 — A study presented at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions, reports significant gender and health insurance disparities in implantable cardioverter defibrillator (ICD) procedures. For the first time in nearly a decade, the new analysis of ICD implants in the United States shows a majority of implants are performed on people with insurance and more commonly in the male population.

ICDs are small devices, about the size of a small cell phone, that are placed below the collarbone. Via wires or leads, these devices continuously monitor the heart’s rhythm. If the heart beats too quickly or too slowly, the ICD issues a jolt of electricity to restore the heart’s normal rhythm. People with heart muscle damage or “heart failure” have greater chance of having a dangerously fast heart rhythm that ICDs treat. ICDs are very effective in stopping life-threatening arrhythmias and considered one of the most successful therapies to treat arrhythmias.

The authors of the study queried data from the National Inpatient Sample from 2000-2011 using ICD-9 procedure codes for ICD implantation. ICD utilization was assessed in the following four groups: male insured, male uninsured, female insured and female uninsured. More than 160,000 (160,296) estimated ICD implants were identified in people over the age of 18. Almost all (95 percent) of the ICD implants identified were performed in the insured population. The male population with insurance (70.8 percent) had significantly higher implants compared with the female population with insurance (24.2 percent). Only 5 percent of the procedures were performed on people who did not have insurance.

“The striking results show that major disparities are present with ICD implants and this further highlights the importance of adhering to guidelines, so best possible candidates have access to the life saving device,” said lead author Nileshkumar Patel, MBBS, Staten Island University Hospital in New York. “We are presented with the challenge to look for new ways to enhance the quality of care and continue to educate on the safety and effectiveness of these devices.”

Abhishek Deshmukh, co-author of the study, cardiologist at University of Arkansas for Medical Sciences added, “On the surface, efforts are made toward the mitigation of disparities, but closer examination shows that there is still more work to be done especially in current challenging healthcare landscape.”

For more information: www.HRSonline.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init